期刊文献+

DNA靶向手性钌(Ⅱ)配合物的合成、表征及其抗肿瘤作用 被引量:3

Synthesis,characterization and inhibitory activity against tumor cells of chiral ruthenium(Ⅱ) complexes targeted to DNA
下载PDF
导出
摘要 目的设计合成2个手性钌(Ⅱ)多吡啶配合物Λ-[Ru(bpy)2(p-NPIP)](PF6)2.2H2O(1)和Λ-[Ru(bpy)2(p-tFPIP)](PF6)2.2H2O(2),评价其体外抗肿瘤活性,并对配合物2与DNA分子的识别机制及其光裂解作用进行初步探讨。方法采用MTT方法评价手性钌(Ⅱ)配合物1和2对肿瘤细胞生长的抑制,并采用电子吸收光谱、荧光光谱和黏度试验等方法研究手性钌配合物2与DNA的分子识别机制;采用凝胶电泳试验评价配合物2对DNA分子的光裂解作用。结果手性钌(Ⅱ)配合物2能够抑制肿瘤细胞的生长,特别是对HO8910PM细胞生长的抑制率IC50=47.8μmol.L-1,与同等条件下顺铂的抗肿瘤活性相当;研究结果表明插入配体上取代基的电子效应对其抗肿瘤活性有较大影响;光谱学试验证明钌多吡啶配合物1和2通过插入方式与DNA结合(Kb=2.86×105 L.mol-1)。结论手性钌(Ⅱ)多吡啶配合物具有一定的抗肿瘤活性,其抗肿瘤活性与钌(Ⅱ)配合物的分子结构及其与DNA分子契合能力相关。 Objective To synthesize and characterize two chiral ruthenium(Ⅱ) complexes Λ-[Ru(bpy)2(p-NPIP)](PF6)2·2H2O(1) and Λ-[Ru(bpy)2(p-tFPIP)](PF6)2·2H2O(2) by ES-MS,1H-NMR and CD spectra,and investigate the antitumor activity of both complexes and its interaction with DNA.Methods The antitumor activity of the two complexes against tumor cells were evaluated by MTT methods,and the interaction of chiral ruthenium(Ⅱ) complex 2 with calf thymus DNA has been investigated by electronic absorption spectra and fluorescent spectra,as well as viscosity measurements.Results The results show that complex 2 exhibits excellent inhibitory activity against HO8910PM cell with IC50=47.8 μmol·L-1,which is comparable to that of cis-platinum at the same conditions,and the chiral ruthenium complex binds to DNA through intercalation mode with binding constant measured with 2.86×10^5 mol·L^-1Conclusion The chiral ruthenium(Ⅱ) complexes exhibit promising anti-tumor activity against varied tumor cells,which involves the binding properties of ruthenium(Ⅱ) complexes with DNA molecules.
出处 《广东药学院学报》 CAS 2011年第5期459-463,共5页 Academic Journal of Guangdong College of Pharmacy
基金 广东省科技计划项目(2007B031513004) 广东药学院青年骨干教师基金
关键词 手性钌配合物 靶向化合物 分子识别 抗肿瘤 chiral ruthenium complex targeted compounds intercalating antitumor
  • 相关文献

参考文献13

  • 1MEI Wen-jie, MA Yu-zhuo, LIU Jie, et al. Experimental and DFT studies on the DNA-binding properties ofruthenium( Ⅱ ) complexes [ Ru (phen)2L]2+ ( L = o- MOP,o-MP,o-CP and o-NP [ J ]. Trans Met Chem, 2006, 31:277 - 285.
  • 2HERGUETA B A,JIMENEZ H M E, MONTERO F,et al. Singlet oxygen-mediated DNA photocleavage with Ru ( Ⅱ ) polypyridyl complexes [ J ]. J Phys Chem B, 2002, 106 :4010 -4017.
  • 3MEI Wei-jie,WANG Na, LIU Yun-jun, et al. Studies on cytotoxic and DNA-binding properties of two ruthenium ( Ⅱ ) complexes of a substituted phenanthroline ligand [J]. Trans Met Chem, 2008,33:499 -503.
  • 4HOLMLIN R E, STEMP E D, BARTON J K. Electron transfer between metal complexes bound to DNA: variations in sepuence, donor, and metal binding mode [ J ]. Inorg Chem, 1998,37:29 - 34.
  • 5STYANARAYANA S, DABROWIAK J C, CHAIRES J B.Neither A- nor A-tris ( phenanthroline ) mthenimn ( ⅡⅠ ) binds to DNA by classical intercalation [ J ]. Biochemstry, 1992,31:9319 - 9322.
  • 6DERVAN P B. Design of sequence-specific DNA-binding molecules [ J]. Science, 1986,232 : 464 - 471.
  • 7MERGNY J L,HELENE C. G-quadruplex DNA: a target for drug design[J]. Nat Meal,1998,4: 1366 - 1367.
  • 8BARTON J K, DANNENBERG J J, RAPHAEL A L. Enantiomeric selectivity in binding tris (phenanthroline) zinc( Ⅱ) to DNA[J]. J Am Chem Soc,1982,104: 4967- 4969.
  • 9MEI Wen-jie, LIU Jie, ZHENG Kai-cheng, et al. Experi- mental and theoretical study on DNA-binding and photocleavage properties of chiral complexes A- and A- [ Ru (bpy)2L] (L = o-hpip,m-hpip and p-hpip) [J]. Dalton Trans, 2003,32 ( 7 ) : 1352 - 1359.
  • 10KUMAR C V,BARTON J K,TURRO N J. Photophysics of ruthenium complexes bound to double helical DNA [ J]. J Am Chem Soc, 1985,107 : 5518 - 5520.

二级参考文献4

  • 1Schuitmaker JJ, Baas P, van Leengoed HLLM, et al. Photodynamic therapy: a promising new modality for the treatment of cancer[ J ]. J Photochem Photobiol B Biol, 1996, 34: 3.
  • 2Chu BWK, Tsang WS, Wong KMC, et al. The eighth international symposium on applied bioinorganic chemistry [ A ].Hongkong University, 2004: 44.
  • 3Sava G, Alessio E, Berganmo A, et al, Topics in biological inorganic chemistry, volume 1, metallo-p harmaceuticals [M]. Berlin:Springer, 1999:143.
  • 4Mei WJ, Liu J, Chao H, et al, DNA-binding and cleavage studies of a novel porphyrin ruthenium mixed complex [MPyTPP-Ru (pip)2 Cl] + [ J ]. Trans Met Chem, 2003, 28:852.

同被引文献42

  • 1庄聪文,钟江明,翁向群,程先进,杨胜生,陈龙,曾志勇,张哲明,陈炜生.胸部多重癌的外科治疗体会(附17例报告)[J].第二军医大学学报,2005,26(7):832-833. 被引量:1
  • 2王榕,林建新,俞秀金,倪军,魏可镁.氨合成铁、钌催化剂联用工艺[J].化工学报,2007,58(1):95-101. 被引量:8
  • 3Brunn H.Two interesting benign lung tumors of contradictoryhistopathology[J].J Thorac Surg,1939,9(2):119-31.
  • 4Umiker WO,Iverson L.Post-inflammatory“tumors”of the lung[J].J Thorac Surg,1954,28(1):55-63.
  • 5Agrons GA,Rosado-de-christenson ML,Kirejczy KWM,et al.Pulmonary inflammatory pseudotumor:radiologic features[J].Radiology,1998,206:511-8.
  • 6Coffin CM,Watterson J,Priest JR,et al.Extrapulmonaryinflammatory myofibroblastic tumor(inflammatory pseudotumor).A clinicopathologic and immunohistochemical study of 84 cases[J].Am J Surg Pathol,1995,19(8):859-72.
  • 7Nakamura H,Kawasaki N,Taguchi M,et al.Pulmonaryinflammatory myofibroblastic tumor resected by video-assistedthoracoscopic surgery:Report of a case[J].Surg Today,2007,37(2):137-40.
  • 8Cerfolio RJ,Allen MS,Nascimento AG,et al.Inflammatorypseudotumors of the lung[J].Ann Thorac Surg,1999,67(4):933-6.
  • 9Kovach SJ,Fischer AC,Katzman PJ,et al.Inflammatorymyofibroblastic tumor[s J].J Surg Oncol,2006,94(5):385-91.
  • 10Berger A,Kim C,Hagstrom N,et al.Successful preoperativetreatment of pediatric bladder inflammatory myofibroblastic tumorwith anti-inflammatory therapy[J].Urology,2007,70(2):372.e13-5.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部